Verastem, Inc. - Margin dodolan resik VSTM

Tandha merek verastem.com (VSTM)

Operational risks for Verastem, Inc. (VSTM) are linked to laboratory capacity constraints, as evidenced by the company's net margin ratio, where the figure stands at -178.40. Stability is maintained through partnerships with research centers and the successful trials of avutometinib for ovarian cancer. FDA approval and patent protection will help curb capital expenditure, minimizing chart volatility.

verastem.com (VSTM) - Rentabilitas dodolan resik saka 04.07.2022 nganti 19.11.2026

Verastem Inc - rincian analitis lan metrik utama (VSTM)

- rega saham lan konsensus proyeksi valuasi:
Ringkesan analitik perusahaan:Verastem Corp - VSTM
Produk dadi Verastem Oncology

Verastem, Inc. focuses on completing clinical trials for targeted oncology drugs to transition to the market sales stage. The net profit margin trend reflects the share of profit after all deductions, allowing investors to identify abnormal R&D expenses and assess the fundamental value stability of the asset prior to the full commercialization of its products.